After decades of work mapping the human genome, we are beginning to reap real benefits through the tools of pharmacobiomics. Particularly in the area of infectious disease, biomics is shedding new light on how disease originates and how the individual immune system responds. Working in conjunction with biomarkers, these new technologies are increasing the ability to diagnose, monitor and manage infections.

Dr. Kelly McKee explores the multi-faceted research in pharmacobiomics and how it will shape the future of pharma and biotech product development. Every new bit of knowledge is leading to more effective approaches to drug and vaccine development — improving product effectiveness as well as delivering process efficiencies.

About the Author  

Kelly T. McKee Jr., M.D., M.P.H.Vice President, Public Health and Government Services, Quintiles  

Dr. McKee has dedicated his career to researching and preventing infectious diseases. Before joining Quintiles in 2006, he served as Senior Director of Clinical Research and Chief Medical Officer for a vaccine development company. After finishing a 20-year career in the U.S. Army Medical Department, he served as the Head of General Communicable Disease Control and State Epidemiologist for North Carolina, but returned to government work at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). He has written over 100 peer-reviewed publications and textbook chapters and reviews manuscripts for several professional journals.